# Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

> **NCT01149434** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 19 (actual)

## Conditions studied

- Cancer
- Neuroendocrine
- Ovarian Cancer
- Colon Cancer

## Interventions

- **DRUG:** JI-101
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01149434
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Lack of drug efficacy
- **Last updated:** 2014-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01149434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01149434, "Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01149434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*